HO-1 up-regulation: A key point in high-risk neuroblastoma resistance to bortezomib

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 4, 2014, Pages 613-622

  Furfaro, Anna Lisa ^a   Piras, Sabrina ^a   Passalacqua, Mario ^a   Domenicotti, Cinzia ^a   Parodi, Alessia ^b   Fenoglio, Daniela ^b   Pronzato, Maria Adelaide ^a   Marinari, Umberto Maria ^a   Moretta, Lorenzo ^c   Traverso, Nicola ^a   Nitti, Mariapaola ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Chemoresistance; Heme oxygenase 1; Neuroblastoma; Redox signaling

Indexed keywords

BORTEZOMIB; HO 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; UPREGULATION;

CHEMORESISTANCE; HEME OXYGENASE-1; NEUROBLASTOMA; REDOX SIGNALING;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; HEME OXYGENASE-1; HUMANS; NEUROBLASTOMA; NF-E2-RELATED FACTOR 2; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PYRAZINES; RISK; UP-REGULATION;

EID: 84893474094     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.12.008     Document Type: Article

References (56)

1. Park J.R., Eggert A., Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol. Oncol. Clin. North Am. 2010, 24:65-86.
2. Ohira M., Nakagawara A. Global genomic and RNA profiles for novel risk stratification of neuroblastoma. Cancer Sci. 2010, 101:2295-2301.
3. Tang X.X., Robinson M.E., Riceberg J.S., Kim D.Y., Kung B., Titus T.B., Hayashi S., Flake A.W., Carpentieri D., Ikegaki N. Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin. Cancer Res. 2004, 10:5837-5844.
4. Balendiran G.K., Dabur R., Fraser D. The role of glutathione in cancer. Cell Biochem. Funct. 2004, 22:343-352.
5. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., Chen W., Yi X., Zheng W., Wondrak G.T., Wong P.K., Zhang D.D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29:1235-1243.
6. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58:262-270.
7. Trakshel G.M., Maines M.D. Multiplicity of heme oxygenase isozymes. HO-1 and HO-2 are different molecular species in rat and rabbit. J. Biol. Chem. 1989, 264:1323-1328.
8. Maines M.D. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 1988, 2:2557-2568.
9. Keyse S.M., Tyrrell R.M. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:99-103.
10. Alam J., Shibahara S., Smith A. Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. J. Biol. Chem. 1989, 264:6371-6375.
11. Patriarca S., Furfaro A.L., Cosso L., Pesce Maineri E., Balbis E., Domenicotti C., Nitti M., Cottalasso D., Marinari U.M., Pronzato M.A., Traverso N. Heme oxygenase 1 expression in rat liver during ageing and ethanol intoxication. Biogerontology 2007, 8:365-372.
12. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
13. Jozkowicz A., Was H., Dulak J. Heme oxygenase-1 in tumors: is it a false friend?. Antioxid. Redox Signal. 2007, 9:2099-2117.
14. Goodman A.I., Choudhury M., da Silva J.L., Schwartzman M.L., Abraham N.G. Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc. Soc. Exp. Biol. Med. 1997, 214:54-61.
15. Maines M.D., Abrahamsson P.A. Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology 1996, 47:727-733.
16. Berberat P.O., Dambrauskas Z., Gulbinas A., Giese T., Giese N., Kunzli B., Autschbach F., Meuer S., Buchler M.W., Friess H. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin. Cancer Res. 2005, 11:3790-3798.
17. Nuhn P., Kunzli B.M., Hennig R., Mitkus T., Ramanauskas T., Nobiling R., Meuer S.C., Friess H., Berberat P.O. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol. Cancer 2009, 8:37.
18. Furfaro A.L., Macay J.R., Marengo B., Nitti M., Parodi A., Fenoglio D., Marinari U.M., Pronzato M.A., Domenicotti C., Traverso N. Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1. Free Radic. Biol. Med. 2012, 52:488-496.
19. Rushworth S.A., Bowles K.M., MacEwan D.J. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res. 2011, 71:1999-2009.
20. Pellom S.T., Shanker A. Development of proteasome inhibitors as therapeutic drugs. J. Clin. Cell. Immunol. 2012, S5:5.
21. Weniger M.A., Rizzatti E.G., Perez-Galan P., Liu D., Wang Q., Munson P.J., Raghavachari N., White T., Tweito M.M., Dunleavy K., Ye Y., Wilson W.H., Wiestner A. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin. Cancer Res. 2011, 17:5101-5112.
22. Mujtaba T., Dou Q.P. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov. Med. 2011, 12:471-480.
23. Urbani S., Caporale R., Lombardini L., Bosi A., Saccardi R. Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells. Cytotherapy 2006, 8:243-253.
24. Kwak M.K., Itoh K., Yamamoto M., Kensler T.W. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol. Cell. Biol. 2002, 22:2883-2892.
25. Frankland-Searby S., Bhaumik S.R. The 26S proteasome complex: an attractive target for cancer therapy. Biochim. Biophys. Acta 2012, 1825:64-76.
26. Wu W.K., Cho C.H., Lee C.W., Wu K., Fan D., Yu J., Sung J.J. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 2010, 293:15-22.
27. Hideshima T., Anderson K.C. Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies. Semin. Hematol. 2012, 49:223-227.
28. Moreau P., Richardson P.G., Cavo M., Orlowski R.Z., San Miguel J.F., Palumbo A., Harousseau J.L. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012, 120:947-959.
29. Muscal J.A., Thompson P.A., Horton T.M., Ingle A.M., Ahern C.H., McGovern R.M., Reid J.M., Ames M.M., Espinoza-Delgado I., Weigel B.J., Blaney S.M. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr. Blood Cancer 2013, 60:390-395.
30. Blum W., Schwind S., Tarighat S.S., Geyer S., Eisfeld A.K., Whitman S., Walker A., Klisovic R., Byrd J.C., Santhanam R., Wang H., Curfman J.P., Devine S.M., Jacob S., Garr C., Kefauver C., Perrotti D., Chan K.K., Bloomfield C.D., Caligiuri M.A., Grever M.R., Garzon R., Marcucci G. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012, 119:6025-6031.
31. Mato A.R., Feldman T., Goy A. Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist 2012, 17:694-707.
32. Brignole C., Marimpietri D., Pastorino F., Nico B., Di Paolo D., Cioni M., Piccardi F., Cilli M., Pezzolo A., Corrias M.V., Pistoia V., Ribatti D., Pagnan G., Ponzoni M. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J. Natl. Cancer Inst. 2006, 98:1142-1157.
33. Pagnan G., Di Paolo D., Carosio R., Pastorino F., Marimpietri D., Brignole C., Pezzolo A., Loi M., Galietta L.J., Piccardi F., Cilli M., Nico B., Ribatti D., Pistoia V., Ponzoni M. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin. Cancer Res. 2009, 15:1199-1209.
34. Rae C., Tesson M., Babich J.W., Boyd M., Mairs R.J. Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species. EJNMMI Res. 2013, 3:73.
35. Du B.Y., Song W., Bai L., Shen Y., Miao S.Y., Wang L.F. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines. Chemotherapy 2012, 58:44-51.
36. Rapino F., Naumann I., Fulda S. Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. Cell Death Dis. 2013, 4:e925.
37. Ohta T., Iijima K., Miyamoto M., Nakahara I., Tanaka H., Ohtsuji M., Suzuki T., Kobayashi A., Yokota J., Sakiyama T., Shibata T., Yamamoto M., Hirohashi S. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008, 68:1303-1309.
38. Jiang T., Chen N., Zhao F., Wang X.J., Kong B., Zheng W., Zhang D.D. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010, 70:5486-5496.
39. Shibata T., Kokubu A., Gotoh M., Ojima H., Ohta T., Yamamoto M., Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008, 135:1358-1368. (1368 e1-4).
40. Chapple S.J., Siow R.C., Mann G.E. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int. J. Biochem. Cell Biol. 2012, 44:1315-1320.
41. Taguchi K., Motohashi H., Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011, 16:123-140.
42. Huang H.C., Nguyen T., Pickett C.B. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem. 2002, 277:42769-42774.
43. Kawai Y., Garduno L., Theodore M., Yang J., Arinze I.J. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J. Biol. Chem. 2011, 286:7629-7640.
44. Farombi E.O., Surh Y.J. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J. Biochem. Mol. Biol. 2006, 39:479-491.
45. Rushworth S.A., Bowles K.M., Raninga P., MacEwan D.J. NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Res. 2010, 70:2973-2983.
46. Chen S., Blank J.L., Peters T., Liu X.J., Rappoli D.M., Pickard M.D., Menon S., Yu J., Driscoll D.L., Lingaraj T., Burkhardt A.L., Chen W., Garcia K., Sappal D.S., Gray J., Hales P., Leroy P.J., Ringeling J., Rabino C., Spelman J.J., Morgenstern J.P., Lightcap E.S. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 2010, 70:4318-4326.
47. Schwer C.I., Mutschler M., Stoll P., Goebel U., Humar M., Hoetzel A., Schmidt R. Carbon monoxide releasing molecule-2 inhibits pancreatic stellate cell proliferation by activating p38 mitogen-activated protein kinase/heme oxygenase-1 signaling. Mol. Pharmacol. 2010, 77:660-669.
48. Tai E., Benchimol S. TRIMming p53 for ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11431-11432.
49. Tsvetkov P., Reuven N., Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ. 2010, 17:103-108.
50. Pariat M., Carillo S., Molinari M., Salvat C., Debussche L., Bracco L., Milner J., Piechaczyk M. Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell. Biol. 1997, 17:2806-2815.
51. Gelman J.S., Sironi J., Berezniuk I., Dasgupta S., Castro L.M., Gozzo F.C., Ferro E.S., Fricker L.D. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One 2013, 8:e53263.
52. Liu X.M., Chapman G.B., Peyton K.J., Schafer A.I., Durante W. Carbon monoxide inhibits apoptosis in vascular smooth muscle cells. Cardiovasc. Res. 2002, 55:396-405.
53. Faraonio R., Vergara P., Di Marzo D., Pierantoni M.G., Napolitano M., Russo T., Cimino F. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J. Biol. Chem. 2006, 281:39776-39784.
54. Bonvini P., Nguyen P., Trepel J., Neckers L.M. In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome. Oncogene 1998, 16:1131-1139.
55. Chen L., Iraci N., Gherardi S., Gamble L.D., Wood K.M., Perini G., Lunec J., Tweddle D.A. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res. 2010, 70:1377-1388.
56. Bell E., Chen L., Liu T., Marshall G.M., Lunec J., Tweddle D.A. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010, 293:144-157.